Glaucoma is a leading cause of blindness in the United States and the world. The current treatment for Glaucoma consists of eye drops usually used one, two or more times each day. Usually more than one drug is prescribed. Due to the frequency of applications required, the largest problem is with patient compliance. The drug under development by CBMS at the University of Arizona has the remarkable prospect of needing to be used only once or twice per year by the patient. The market for Glaucoma treatment is huge. It is projected that by 2010 there will be 60.5 million people with the most common form of Glaucoma. .Novartis alone sells over $1.5 billion of Glaucoma medications annually. AMD is the leading cause of blindness worldwide, for people over 55 years of age. There is currently no cure for the disease.

Several large companies are working with product development drugs which are still experimental and extremely expensive. The drug under development by CBMS has the benefits of requiring fewer treatments then current drugs, and will be far less expensive.

There is extensive intellectual property with U.S .and world patents issued and pending.

Information: info@canadianbiomed.com